Indegene Acquires BioPharm for $106 Million to Strengthen AI-Powered Pharma Marketing

Healthcare technology firm Indegene has announced the acquisition of BioPharm, a Pennsylvania-based marketing services agency and part of Omnicom Health Group, for $106 million. The deal, executed via Indegene’s subsidiary ILSL Inc., aims to enhance Indegene’s commercialization portfolio and expand its AI-driven marketing and AdTech capabilities for global pharmaceutical companies.

Expanding Capabilities in Data-Driven Pharma Marketing

BioPharm specializes in marketing and communications solutions for life sciences clients across North America, serving 17 of the world’s top 25 biopharma companies. The agency offers expertise in omnichannel strategy, analytics, automation, and targeted engagement, employing over 90 professionals and generating $38.13 million in revenue in 2024.

Strategic Growth and Industry Impact

Manish Gupta, Chairman and CEO of Indegene, stated that the acquisition reinforces Indegene’s position as a preferred tech-native commercialization partner in the life sciences sector. The integration of BioPharm’s capabilities is expected to deliver advanced, AI-powered marketing solutions, driving more efficient engagement with healthcare providers and supporting clients’ global commercialization strategies.